Alzinova AB (publ) announced that all patients in the high dose cohort have received the first dose in the company's ongoing phase 1b study with the vaccine candidate ALZ-101. The treatment is given four times to a total of six patients during a 16-week period and each patient is then followed up for another four weeks. The company plans to present data from the high-dose cohort in the fourth quarter of 2024.

Alzinova announced at the end of June that all patients had been recruited to the high-dose part of the company's phase 1b study with the vaccines candidate ALZ-101. Now all patients have also received the first dose of ALZ-101. In total, all patients will be treated on four occasions during a 16-week period, and then each patient will be followed up for another four week.

The purpose of the high-dose cohort is to evaluate a higher dose of the vaccine candidate AL Z-101 ahead of an upcoming clinical phase 2 study. By evaluating a higher dose, the company can partly strengthen knowledge about the vaccine candidate, partly optimize the conditions and the study design in the phase 2 study.